Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Shah

Showing results (51-60 of 119) with videos related to

Pageof 12
Sort By:
Blood|February 23, 2013
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDCatherine C Smith, Elisabeth A Lasater, Xiaotian Zhu, et al.
Cancer|March 22, 2016
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicityCharles A Schiffer, Jorge E Cortes, Andreas Hochhaus, et al.
Scientific Reports|March 1, 2018
Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KITJaideep B Bharate, Nicholas McConnell, Gunaganti Naresh, et al.
Annals of Hematology|May 24, 2017
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratiosGiuseppe Saglio, Philipp le Coutre, Jorge Cortes, et al.
Cureus|June 12, 2023
Telemedicine Evaluation of Hip AilmentsRock P Vomer, Emma York, Kristina DeMatas, et al.
Cancer|June 19, 2009
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, et al.
Cancer Discovery|December 24, 2013
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addictionJennifer Asmussen, Elisabeth A Lasater, Cheryl Tajon, et al.
American Journal of Hematology|May 20, 2016
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034Neil P Shah, Philippe Rousselot, Charles Schiffer, et al.
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
European Journal of Medicinal Chemistry|September 3, 2021
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitorLingtian Zhang, Naga Rajiv Lakkaniga, Jaideep B Bharate, et al.
Pageof 12

Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Blood|February 23, 2013
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDCatherine C Smith, Elisabeth A Lasater, Xiaotian Zhu, et al.
Cancer|March 22, 2016
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicityCharles A Schiffer, Jorge E Cortes, Andreas Hochhaus, et al.
Scientific Reports|March 1, 2018
Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KITJaideep B Bharate, Nicholas McConnell, Gunaganti Naresh, et al.
Annals of Hematology|May 24, 2017
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratiosGiuseppe Saglio, Philipp le Coutre, Jorge Cortes, et al.
Cureus|June 12, 2023
Telemedicine Evaluation of Hip AilmentsRock P Vomer, Emma York, Kristina DeMatas, et al.
Cancer|June 19, 2009
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, et al.
Cancer Discovery|December 24, 2013
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addictionJennifer Asmussen, Elisabeth A Lasater, Cheryl Tajon, et al.
American Journal of Hematology|May 20, 2016
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034Neil P Shah, Philippe Rousselot, Charles Schiffer, et al.
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
European Journal of Medicinal Chemistry|September 3, 2021
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitorLingtian Zhang, Naga Rajiv Lakkaniga, Jaideep B Bharate, et al.
Pageof 12